References
- The National Health Service health technology assessment programme. Available from http://www.hta.ac.uk [Last accessed 17 Aug 2006]
- The National Health Service health technology assessment programme. Available from http://www.hta.nhsweb.nhs.uk [Last accessed 17 Aug 2006]
- Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003:CD001186
- Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003:CD002893
- Olaguibel JM, Alvarez-Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusion from one meta-analysis. J Invest Allergol Clin Immunol 2005; 15:9–16
- Calamita Z, Saconato H, Pelà AB, et al. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized clinical trials using the Cochrane Collaboration method. Allergy 2006;61:1162–72
- Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006;97:141–8
- Bousquet J, van Cauwenberge P, editors. Allergic rhinitis and its impact on asthma (ARIA). Position Paper endorsed by WHO. J Allergy Clin Immunol 2001;108(Suppl 5):147–334
- Ministero della Sanità. Nomenclatore Tariffario delle prestazioni ambulatoriali DM 22.7.96; Gazzetta Ufficiale n 216, 14.9.96
- Giofil Database of Drug Prices. Available from http://www. giofil.it [Last accessed 20 May 2006]
- Stallergenes, data on file, 2006
- ISPOR Real World Task Force. ISPOR using ‘real world’ data task force draft report. Available from http://www.ispor.org/ workpaper/real_world_data.asp [Last accessed 22 Aug 2006]
- Ariano R, Berto P, Tracci D, et al. Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy Asthma Proc 2006;27:159–63
- Buchner K, Siepe M. Nutzen der Hyposensibilierung unter wirtschaftlichen Aspekten. Allergo J 1995;4:156–63
- Fischer P. Therapie des allergisches Asthma. Die spezifische Hyposensibilierung kann helfen Kosten in Milliardenhohe einzusparen. Laryngo-Rhino-Otologie 1995;74:28
- Le Pen C, Rumeau-Pichen C, Lillin H. L’impact de l’immunothérapie specifique sur le couts directs de la maladie allergique: une etude pragmatique. Rev Franc All Immunol Clin 1997:37:11–14
- Schadlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000;17:37–52
- Berto P, Bassi M, Incorvaia C, et al. Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma. Allerg Immunol (Paris) 2005;37:303–8
- Berto P, Passalacqua G, Crimi N, et al. Economic Evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Ann Allergy Asthma Immunol 2006;97:615–21
- Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. Arch Intern Med 1999;159:941–55
- Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006;354:1985–97
- Bollettino polline. Available from http://www.pollineallergia.net [Last accessed 13 Sept 2007]
- Di Rienzo V, Pucci S, D’Alò S, et al. Effects of high-dose sublingual immunotherapy on quality of life in patients with cypress-induced rhinitis: a placebo-controlled study. Clin Exp Allergy Rev 2006;6:67–70
- Ariano R, Amoroso S, Astarita C, et al. Quality of life in allergic rhinitis and impact of high-dose sublingual immunotherapy: a real-life study. Clin Exp Allergy Rev 2006;71–73